RBC Capital on Sarepta (SRPT): 'KOL Feedback Suggests Elevidys Use Unlikely To Pick Back Up in '26' Jan 26, 2026 05:18AM
RBC Capital weighs in on Sarepta Therapeutics (SRPT) related to two new FAERS Elevidys deaths Aug 4, 2025 02:26PM
Sarepta Therapeutics (SRPT) PT Lowered to $58 at RBC Capital as 'Elevidys Hits A Wall' May 7, 2025 09:31AM
US FDA names agency critic Vinay Prasad as top vaccine official May 6, 2025 03:32PM
RBC makes changes to its flagship 'Top 30 Global Ideas for 2025' list Apr 1, 2025 10:00AM
View Older Stories

Feb 27, 2025 08:47AM RBC on Sarepta Therapeutics (SRPT): 'Overall We View Shares as Fundamentally Undervalued'; PT Lowered
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 16, 2024 07:03AM RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
Aug 8, 2024 06:27AM Sarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
Jul 29, 2024 05:04AM RBC Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jun 21, 2024 04:50AM Sarepta Therapeutics (SRPT) PT Raised to $182 at RBC Capital
Jun 20, 2024 07:23AM RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
May 28, 2024 05:16AM RBC Capital Downgrades Sarepta Therapeutics (SRPT) to Sector Perform
May 2, 2024 06:52AM Sarepta Therapeutics (SRPT) PT Lowered to $141 at RBC Capital
May 24, 2023 08:48AM RBC Capital Defending Sarepta Therapeutics (SRPT), 'we believe weakness presents a buying opportunity'
Apr 21, 2022 10:33AM RBC Capital Defending Sarepta Therapeutics (SRPT), 'we see value in SRPT's gene therapy programs that is not captured at current levels and remain buyers', PT $150
Oct 14, 2021 05:44AM Sarepta Therapeutics (SRPT) Prices 6.17M Share Offering at $81/sh
Oct 13, 2021 09:15PM Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
Mar 12, 2021 06:08AM Sarepta Therapeutics (SRPT) PT Raised to $133 as RBC Capital Sees a Slim Possibility of an Early Filing
Sep 18, 2020 06:25AM 3 Reasons RBC Capital Thinks the Sarepta Therapeutics (SRPT) Patent Infringement Suit is not Meaningful
Jun 18, 2020 09:26AM Pre-Open Stock Movers 06/18: (ALPN) (AEMD) (ELOX) Higher; (LPTX) (QUIK) (BIIB) Lower (more...)
May 12, 2020 04:30PM Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
Feb 27, 2020 06:21AM Sarepta Therapeutics (SRPT) PT Raised to $213 at RBC Capital
Feb 25, 2020 11:03AM Sarepta Therapeutics (SRPT) May Have Sold Priority Review Voucher to Vifor - RBC
Jan 22, 2020 09:36AM RBC Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT) on Release of Full CRL Letter
Dec 23, 2019 08:05AM Sarepta Therapeutics (SRPT) PT Lowered to $200 at RBC Capital
Dec 13, 2019 06:19AM Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
Oct 10, 2019 07:12AM Sarepta Therapeutics (SRPT) Defended at RBC
Sep 24, 2019 07:32AM Sarepta Therapeutics (SRPT) Presenting Functional LGMD2E Data on 10/5 - RBC Capital
Aug 20, 2019 06:43AM Sarepta Therapeutics (SRPT) PT Lowered to $204 at RBC Capital
Aug 8, 2019 07:50PM Sarepta says adverse event report for DMD gene therapy erroneously submitted
Aug 8, 2019 01:08PM FDA Adverse Event May Not Be 'Major Showstopper' for Sarepta Therapeutics (SRPT) Program - RBC
Aug 8, 2019 07:04AM Sarepta Therapeutics (SRPT) PT Lowered to $218 at RBC Capital
Jul 1, 2019 06:18AM Sarepta Therapeutics (SRPT) PT Raised to $220 at RBC Capital; Emrges as Clear Leader in DMD
May 14, 2019 08:59AM Sarepta (SRPT) Has $3B +Additional Opportunity Beyond DMD/LGMD - RBC
May 9, 2019 06:49AM Sarepta Therapeutics (SRPT) PT Lowered to $188 at RBC Capital
Feb 28, 2019 06:51AM Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
Jan 17, 2019 06:41AM RBC Capital Weighs in Sarepta Therapeutics (SRPT) Confusion/Skepticism; Trims PT to $164
Jan 7, 2019 03:06PM UPDATE: Sarepta Therapeutics (SRPT) Defended at RBC Capital
Jan 3, 2019 03:59PM Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
Oct 25, 2018 07:30AM Sarepta Therapeutics (SRPT) PT Lowered to $190 at RBC Capital
Oct 4, 2018 09:58AM KOL Agrees that Sarepta (SRPT) High Microdystrophin Expression is Not Worrisome - RBC
Sep 26, 2018 07:29AM Sarepta Therapeutics (SRPT) PT Raised to $200 at RBC Capital Following Management Meetings
Aug 9, 2018 08:48AM Sarepta Therapeutics (SRPT) PT Lowered to $187 at RBC Capital
Jun 20, 2018 07:13AM Sarepta Therapeutics (SRPT) PT Raised to $189 at RBC Capital
Jun 18, 2018 10:19AM RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
May 31, 2018 03:56PM RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
May 18, 2018 10:33AM Sarepta Therapeutics (SRPT) PT Raised to $112 at RBC Capital
May 4, 2018 08:50AM Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
Apr 3, 2018 06:07AM RBC Likes Set-Up for Sarepta Therapeutics (SRPT) Shares
Mar 12, 2018 09:40AM Sarepta Therapeutics (SRPT) PT Raised to $91 at RBC Capital
Jan 22, 2018 05:43AM RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform
Oct 17, 2017 06:33AM Sarepta Therapeutics (SRPT): Neurologists Survey Shows Strong Adoption of Exondys 51 - RBC
View Older Stories